Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 AUD | -1.10% | 0.00% | +14.41% |
Apr. 16 | XRF Scientific's Profit Before Tax Rises 15% in March Quarter | MT |
Feb. 20 | XRF Scientific Shares Decline 5% Despite Higher Fiscal H1 Revenue, EPS | MT |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 24.76 | 32.12 | 63.92 | 77.46 | 160.3 | 188.5 | - | - |
Enterprise Value (EV) 1 | 23.78 | 32.12 | 59.48 | 73.58 | 152 | 177.6 | 173.1 | 168.2 |
P/E ratio | - | 10.4 x | 12.5 x | 12.7 x | 20.9 x | 21 x | 18.7 x | 17.5 x |
Yield | 5.41% | 5.83% | 4.21% | 4.39% | 2.82% | 2.27% | 2.56% | 3.15% |
Capitalization / Revenue | 0.85 x | 1.1 x | 2.04 x | 1.94 x | 2.9 x | 3.19 x | 2.95 x | 2.77 x |
EV / Revenue | 0.82 x | 1.1 x | 1.9 x | 1.84 x | 2.75 x | 3.01 x | 2.71 x | 2.47 x |
EV / EBITDA | 5.8 x | 5.73 x | 8.27 x | 7.82 x | 11.5 x | 11.5 x | 10.1 x | 9.29 x |
EV / FCF | 7.09 x | 81.1 x | 15.4 x | - | 19.8 x | 23.4 x | 18.8 x | 16.5 x |
FCF Yield | 14.1% | 1.23% | 6.49% | - | 5.04% | 4.28% | 5.31% | 6.06% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 133,826 | 133,826 | 134,561 | 135,892 | 137,050 | 138,109 | - | - |
Reference price 2 | 0.1850 | 0.2400 | 0.4750 | 0.5700 | 1.170 | 1.365 | 1.365 | 1.365 |
Announcement Date | 8/26/19 | 8/24/20 | 8/23/21 | 8/22/22 | 8/20/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 29.03 | 29.1 | 31.29 | 40.01 | 55.26 | 59.1 | 63.8 | 68 |
EBITDA 1 | 4.1 | 5.607 | 7.195 | 9.41 | 13.18 | 15.4 | 17.1 | 18.1 |
EBIT 1 | 3.246 | 4.362 | 5.961 | 8.233 | 11.97 | 13.8 | 15.5 | 16.5 |
Operating Margin | 11.18% | 14.99% | 19.05% | 20.58% | 21.66% | 23.35% | 24.29% | 24.26% |
Earnings before Tax (EBT) 1 | - | 4.454 | 6.788 | 8.193 | 11.79 | 13.6 | 15.2 | 16.2 |
Net income 1 | 2.138 | 3.1 | 5.13 | 6.084 | 7.686 | 8.9 | 10 | 10.7 |
Net margin | 7.36% | 10.65% | 16.39% | 15.21% | 13.91% | 15.06% | 15.67% | 15.74% |
EPS 2 | - | 0.0230 | 0.0380 | 0.0450 | 0.0560 | 0.0650 | 0.0730 | 0.0780 |
Free Cash Flow 1 | 3.355 | 0.3959 | 3.859 | - | 7.659 | 7.6 | 9.2 | 10.2 |
FCF margin | 11.56% | 1.36% | 12.33% | - | 13.86% | 12.86% | 14.42% | 15% |
FCF Conversion (EBITDA) | 81.83% | 7.06% | 53.63% | - | 58.13% | 49.35% | 53.8% | 56.35% |
FCF Conversion (Net income) | 156.96% | 12.77% | 75.21% | - | 99.65% | 85.39% | 92% | 95.33% |
Dividend per Share 2 | 0.0100 | 0.0140 | 0.0200 | 0.0250 | 0.0330 | 0.0310 | 0.0350 | 0.0430 |
Announcement Date | 8/26/19 | 8/24/20 | 8/23/21 | 8/22/22 | 8/20/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 15.74 | 13.36 | 14.96 | 16.33 | - | - | 28.17 | 28.62 | 30.6 |
EBITDA | - | 2.686 | 3.118 | 4.18 | - | - | - | - | - |
EBIT 1 | - | 2.031 | 2.612 | 3.57 | - | - | 6.258 | - | 7.4 |
Operating Margin | - | 15.21% | 17.46% | 21.85% | - | - | 22.22% | - | 24.18% |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
Net income | - | 1.474 | 2.382 | 2.748 | 2.792 | 3.738 | - | 4.481 | - |
Net margin | - | 11.04% | 15.92% | 16.83% | - | - | - | 15.65% | - |
EPS 2 | 0.0120 | 0.0110 | 0.0180 | 0.0200 | 0.0210 | 0.0280 | 0.0280 | - | 0.0320 |
Dividend per Share 2 | - | - | - | 0.0200 | - | - | - | - | 0.0310 |
Announcement Date | 2/20/20 | 8/24/20 | 2/22/21 | 8/23/21 | 2/21/22 | 2/20/23 | 8/20/23 | 2/19/24 | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 0.98 | - | 4.43 | 3.88 | 8.33 | 10.9 | 15.4 | 20.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 3.36 | 0.4 | 3.86 | - | 7.66 | 7.6 | 9.2 | 10.2 |
ROE (net income / shareholders' equity) | 6.52% | 8.49% | 12% | - | 16.3% | 15.4% | 15.6% | 15.1% |
ROA (Net income/ Total Assets) | 5.37% | 6.79% | 9.59% | - | 12.4% | 24% | 25.7% | 26.5% |
Assets 1 | 39.81 | 45.67 | 53.52 | - | 62.05 | 37.08 | 38.91 | 40.38 |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share 2 | 0.0300 | - | - | - | 0.0600 | 0.0700 | 0.0800 | 0.0800 |
Capex 1 | 0.52 | 0.75 | 0.41 | 0.37 | 0.76 | 1.8 | 1.3 | 1 |
Capex / Sales | 1.8% | 2.59% | 1.32% | 0.93% | 1.37% | 3.05% | 2.04% | 1.47% |
Announcement Date | 8/26/19 | 8/24/20 | 8/23/21 | 8/22/22 | 8/20/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.41% | 124M | |
+25.41% | 29.45B | |
+33.84% | 5.67B | |
+34.86% | 4.96B | |
+15.00% | 1.52B | |
+11.61% | 1.1B | |
-24.99% | 990M | |
+21.36% | 971M | |
-45.39% | 787M | |
+1.89% | 447M |
- Stock Market
- Equities
- XRF Stock
- Financials XRF Scientific Limited